Panel recommends phase 2/3 trials of Covaxin on children
  • 3 years ago
Even as India battles the 2nd coronavirus wave, the threat of a third wave looms. And experts say that it will be children who will be most vulnerable. Already, several children below the age of 18 years and newborns are testing positive for Covid-19. Bharat Biotech's Covaxin recommended by an expert panel for phase 2/3 trials on children aged between 2 and 18 years. Watch the video to know more.